Fiche publication
Date publication
mars 2024
Journal
Med (New York, N.Y.)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Solitano V, Jairath V, Ungaro F, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
The pivotal role of TL1A in modulating immune pathways crucial for inflammatory bowel disease (IBD) and intestinal fibrosis offers a promising therapeutic target. Phase 2 trials (TUSCANY and ARTEMIS-UC) evaluating an anti-TL1A antibody show progress in expanding IBD therapeutic options. First-in-human data reveal reduced expression of genes associated with extracellular matrix remodeling and fibrosis post-anti-TL1A treatment. Investigational drug TEV-48574, potentially exerting dual antifibrotic and anti-inflammatory effects, is undergoing a phase 2 basket study in both ulcerative colitis (UC) and Crohn disease (CD). Results are eagerly awaited, marking advancements in IBD therapeutics. This critical review comprehensively examines the existing literature, illuminating TL1A and the intricate role of DR3 in IBD, emphasizing the evolving therapeutic landscape and ongoing clinical trials, with potential implications for more effective IBD management.
Mots clés
DR3, PF-06480605, PRA023, TEV-48574, TL1A, TNF/TNFR superfamily, biomarker, chronic immunological diseases, gut inflammation, intestinal fibrosis, mucosal homeostasis
Référence
Med. 2024 03 26;:
